

85. (New) The method of claim 83 wherein said anthracycline is ruboxyl.

REMARKS

Claims 63-85 are pending in this application. Claims 1-62 are canceled without prejudice. Applicants reserve the right to file one or more continuing applications directed to the subject matter of these canceled claims.

New claims 63-85 are presented herein. Independent claim 63 replaces and is similar in scope to claim 34, which was objected to by the Examiner as being dependent on a rejected claim, but was deemed to be allowable if rewritten in independent form. Claims 64-68 are dependent on claim 63, and support for these claims is found at claims 35 and 5-8.

Independent claim 69 replaces and is similar in scope to claim 36, which was objected to by the Examiner as being dependent on a rejected claim, but was deemed to be allowable if rewritten in independent form. Claims 70-73 are dependent on claim 69, and support for these claims is found at claims 37 and 13-15.

Independent claim 74 replaces and is similar in scope to claim 38, which was objected to by the Examiner as being dependent on a rejected claim, but was deemed to be allowable if rewritten in

independent form. Claims 75-79 are dependent on claim 74, and support for these claims is found at claims 39 and 20-23.

Independent claim 80 replaces and is similar in scope to claim 32, which was objected to by the Examiner as being dependent on a rejected claim, but was deemed to be allowable if rewritten in independent form. Claims 81-85 are dependent on claim 80, and support for these claims is found at claims 33 and 28-31.

No new matter is added to the application by virtue of these amendments.

An appendix is attached hereto for showing marked up versions of these claims.

The application now contains 23 total claims including 4 independent claims. Applicants have previously paid for 62 total claims including 8 independent claims. Therefore, no excess claims fees are due. Nevertheless, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment in connection with this response to Deposit Account No. 50-0836.

Rejections under 35 U.S.C. § 102

Claims 9-11, 13-15, 46, 48, and 49 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Alakhov et al. Further, Claims 9-11 and 46 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Michaels. All of these claims

have been canceled. Therefore, the rejections thereof have been rendered moot, and withdrawal of the rejections is respectfully requested.

Rejections under 35 U.S.C. § 103

Claims 1-3, 5-11, 13-19, 21-26, 28-31, 40, 42-46, 48-51, 53-57, and 59-62 were rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Alakhov et al. in view of Unger et al. '430. All of these claims have been canceled. Therefore, the rejections thereof have been rendered moot, and withdrawal of the rejection is respectfully requested.

Claims Objected to as Dependent on a Rejected Claim

Claims 4, 12, 20, 27, 32-39, 41, 47, 52, and 58 were objected to as dependent on a rejected claim. All of these claims have been canceled. However, claims 32, 34, 36, and 38 have been rewritten in independent form as new claims 63, 69, 74, and 80, respectively. The Examiner suggested that these claims would be allowable as such. Claims 33, 35, 37, and 39 have been rewritten as dependent claims to their respective antecedent and now independent claims. Additionally, other subject matter has been claimed as dependent to the new independent claims. Therefore, it is respectfully submitted that claims 63-85 are in condition for allowance.


Conclusion

Should the Examiner deem it advisable to conduct a telephone interview for any reason, the undersigned attorney would be most agreeable to receiving a telephone call to expedite the prosecution of the application.

For the reasons given above, Applicants respectfully request reconsideration and allowance of Claims 63-85 and passage of this application to issue.

DATED this 17<sup>th</sup> day of July, 2002.

Respectfully submitted,



---

Alan J. Howarth, Ph.D.  
Attorney Registration No. 36,553  
Customer No. 020450

Clayton, Howarth & Cannon, P.C.  
P.O. Box 1909  
Sandy, UT 84091  
Telephone: (801) 255-5335  
Facsimile: (801) 255-5338

Version with Markings to Show Changes Made

Please cancel claims 1-62, without prejudice.

Please add the following new claims to the application:

63. (New) A method for delivery of a drug to a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core to said selected site.

64. (New) The method of claim 63 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

65. (New) The method of claim 63 wherein said drug is hydrophobic.

66. (New) The method of claim 65 wherein said hydrophobic drug is an anthracycline.

67. (New) The method of claim 66 wherein said anthracycline is doxorubicin.

68. (New) The method of claim 66 wherein said anthracycline is ruboxyl.

69. (New) A composition for delivery of a hydrophobic drug to a selected site in a patient comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said hydrophobic drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer.

70. (New) The composition of claim 69 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

71. (New) The composition of claim 69 wherein said hydrophobic drug is an anthracycline.

72. (New) The composition of claim 71 wherein said anthracycline is doxorubicin.

73. (New) The composition of claim 71 wherein said anthracycline is ruboxyl.

74. (New) A method for enhancing uptake of a drug by cells at a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core and taken up by said cells.

75. (New) The method of claim 74 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

76. (New) The method of claim 74 wherein said drug is hydrophobic.

77. (New) The method of claim 76 wherein said hydrophobic drug is an anthracycline.

78. (New) The method of claim 77 wherein said anthracycline is doxorubicin.

79. (New) The method of claim 77 wherein said anthracycline is ruboxyl.

80. (New) A method for reducing side effects in a patient from administration of a drug comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said patient such that said drug is released from said hydrophobic core.

81. (New) The method of claim 80 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

82. (New) The method of claim 80 wherein said drug is hydrophobic.

83. (New) The method of claim 82 wherein said hydrophobic drug is an anthracycline.

84. (New) The method of claim 83 wherein said anthracycline is doxorubicin.

85. (New) The method of claim 83 wherein said anthracycline is ruboxyl.